An Update on the Prognostic and Predictive Serum Biomarkers in Metastatic Prostate Cancer

Helen Saxby; Christos Mikropoulos; Stergios Boussios

doi:10.3390/diagnostics10080549

journal article Open Access Jul 31, 2020

An Update on the Prognostic and Predictive Serum Biomarkers in Metastatic Prostate Cancer

Helen Saxby Christos Mikropoulos

Stergios Boussios

Diagnostics Vol. 10 No. 8 pp. 549 · MDPI AG

View at Publisher Save 10.3390/diagnostics10080549

Abstract

Serum biomarkers are molecules produced by normal and abnormal cells. Prostate specific antigen (PSA) is an example of a serum biomarker used widely in the diagnosis and prognostication of prostate cancer. PSA has its limitations as it is organ- but not cancer-specific. The aim of this review is to summarize the current published data on the potential prognostic and predictive biomarkers in metastatic prostate cancer (mPC) that can be used in conjunction with PSA. These biomarkers include microRNAs, androgen receptor variants, bone metabolism, neuroendocrine and metabolite biomarkers, and could guide treatment selection and sequence in an era where we strive to personalized therapy.

Topics

No keywords indexed for this article. Browse by subject →

References

55

[1]

Jemal "Cancer statistics, 2008" CA Cancer J. Clin. (2008) 10.3322/ca.2007.0010

[2]

Global Cancer Incidence and Mortality Rates and Trends—An Update

Lindsey A. Torre, Rebecca L. Siegel, Elizabeth M. Ward et al.

Cancer Epidemiology, Biomarkers & Prevention 2016 10.1158/1055-9965.epi-15-0578

[3]

Terada "Prognostic and predictive biomarkers in prostate cancer: Latest evidence and clinical implications" Ther. Adv. Med. Oncol. (2017) 10.1177/1758834017719215

[4]

Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

Freddie Bray, Jacques Ferlay, Isabelle Soerjomataram et al.

CA: A Cancer Journal for Clinicians 2018 10.3322/caac.21492

[5]

Lara "Serum biomarkers of bone metabolism in castration-resistant prostate cancer patients with skeletal metastases: Results from SWOG 0421" J. Natl. Cancer Inst. (2014) 10.1093/jnci/dju013

[6]

Thoms "Plasma osteopontin as a biomarker of prostate cancer aggression: Relationship to risk category and treatment response" Br. J. Cancer (2012) 10.1038/bjc.2012.345

[7]

Sato, H., Narita, S., Tsuchiya, N., Koizumi, A., Nara, T., Kanda, S., Numakura, K., Tsuruta, H., Maeno, A., and Saito, M. (2018). Impact of early changes in serum biomarkers following androgen deprivation therapy on clinical outcomes in metastatic hormone-sensitive prostate cancer. BMC Urol., 18. 10.1186/s12894-018-0353-4

[8]

Yigitbasi "Prognostic factors in metastatic prostate cancer" Urol. Oncol. (2011) 10.1016/j.urolonc.2009.03.013

[9]

Locke "Next generation biomarkers in prostate cancer" Front. Biosci. (2016) 10.2741/4391

[10]

Martin "Emerging biomarkers of prostate cancer (Review)" Oncol. Rep. (2012) 10.3892/or.2012.1832

[11]

Bjartell "Tumour markers in prostate cancer II: Diagnostic and prognostic cellular biomarkers" Acta. Oncol. (2011) 10.3109/0284186x.2010.531284

[12]

Kontos "Prognostic and predictive biomarkers in prostate cancer" Expert. Rev. Mol. Diagn. (2015) 10.1586/14737159.2015.1110022

[13]

Brase "Circulating miRNAs are correlated with tumor progression in prostate cancer" Int. J. Cancer (2011) 10.1002/ijc.25376

[14]

Bryant "Changes in circulating microRNA levels associated with prostate cancer" Br. J. Cancer (2012) 10.1038/bjc.2011.595

[15]

Patil "MicroRNA in prostate cancer: Practical aspects" Histol. Histopathol. (2015)

[16]

Bhagirath "microRNA-1246 Is an Exosomal Biomarker for Aggressive Prostate Cancer" Cancer Res. (2018) 10.1158/0008-5472.can-17-2069

[17]

Zhang "Serum miRNA-21: Elevated levels in patients with metastatic hormone-refractory prostate cancer and potential predictive factor for the efficacy of docetaxel-based chemotherapy" Prostate (2011) 10.1002/pros.21246

[18]

Tinay "Functional roles and potential clinical application of miRNA-345-5p in prostate cancer" Prostate (2018) 10.1002/pros.23650

[19]

Luu, H.N., Lin, H.Y., Sørensen, K.D., Ogunwobi, O.O., Kumar, N., Chornokur, G., Phelan, C., Jones, D., Kidd, L., and Batra, J. (2017). miRNAs associated with prostate cancer risk and progression. BMC Urol., 17. 10.1186/s12894-017-0206-6

[20]

Nguyen "Expression differences of circulating microRNAs in metastatic castration resistant prostate cancer and low-risk, localized prostate cancer" Prostate (2013) 10.1002/pros.22572

[21]

Ibrahim, N.H., Abdellateif, M.S., Thabet, G., Kassem, S.H., El-Salam, M.A., El-Leithy, A.A., and Selim, M.M. (2019). Combining PHI and miRNAs as biomarkers in prostate cancer diagnosis and prognosis. Clin. Lab., 65. 10.7754/clin.lab.2019.181213

[22]

Lin "Circulating microRNAs are associated with docetaxel chemotherapy outcome in castration-resistant prostate cancer" Br. J. Cancer (2014) 10.1038/bjc.2014.181

[23]

Bhagirath "Role of a novel race-related tumor suppressor microRNA located in frequently deleted chromosomal locus 8p21 in prostate cancer progression" Carcinogenesis (2019) 10.1093/carcin/bgz058

[24]

Zhang "An elevated serum miR-141 level in patients with bone-metastatic prostate cancer is correlated with more bone lesions" Asian. J. Androl. (2013) 10.1038/aja.2012.116

[25]

Peng "Decreased miR-218-5p levels as a serum biomarker in bone metastasis of prostate cancer" Oncol. Res. Treat. (2019) 10.1159/000495473

[26]

Sciarra "Androgen receptor variant 7 (AR-V7) in sequencing therapeutic agents for castratrion resistant prostate cancer: A critical review" Medicine (2019) 10.1097/md.0000000000015608

[27]

Antonarakis "Clinical significance of androgen receptor splice variant-7 mRNA detection in circulating tumor cells of men with metastatic castration-resistant prostate cancer treated with first-and second-line abiraterone and enzalutamide" J. Clin. Oncol. (2017) 10.1200/jco.2016.70.1961

[28]

Antonarakis "AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer" N. Engl. J. Med. (2014) 10.1056/nejmoa1315815

[29]

Boussios "Metastatic Spinal Cord Compression: Unraveling the Diagnostic and Therapeutic Challenges" Anticancer. Res. (2018) 10.21873/anticanres.12817

[30]

Izumi "Increases in bone turnover marker levels at an early phase after starting zoledronic acid predicts skeletal-related events in patients with prostate cancer with bone metastasis" BJU Int. (2012) 10.1111/j.1464-410x.2011.10192.x

[31]

Jung "Bone turnover markers in serum and urine as diagnostic, prognostic and monitoring biomarkers of bone metastasis" Biochim. Biophys. Acta (2014)

[32]

Alcaraz "Usefulness of bone turnover markers as predictors of mortality risk, disease progression and skeletal-related events appearance in patients with prostate cancer with bone metastases following treatment with zoledronic acid: TUGAMO study" Br. J. Cancer (2013) 10.1038/bjc.2013.270

[33]

Kamiya "Implications of serum bone turnover markers in prostate cancer patients with bone metastasis" Urology (2010) 10.1016/j.urology.2009.11.049

[34]

Jung "Bone turnover markers as predictors of mortality risk in prostate cancer patients with bone metastases following treatment with zoledronic acid" Eur. Urol. (2011) 10.1016/j.eururo.2010.12.006

[35]

Sonpavde "Serum alkaline phosphatase changes predict survival independent of PSA changes in men with castration-resistant prostate cancer and bone metastasis receiving chemotherapy" Urol. Oncol. (2012) 10.1016/j.urolonc.2010.07.002

[36]

Wang "Predictive value of serum bone sialoprotein and prostate-specific antigen doubling time in patients with bone metastasis of prostate cancer" J. Huazhong Univ. Sci. Technol. Med. Sci. (2013) 10.1007/s11596-013-1158-z

[37]

Conteduca "Plasma androgen receptor and serum chromogranin A in advanced prostate cancer" Sci. Rep. (2018) 10.1038/s41598-018-33774-4

[38]

Genitsch, V., Zlobec, I., Seiler, R., Thalmann, G.N., and Fleischmann, A. (2017). Neuroendocrine differentiation in metastatic conventional prostate cancer is significantly increased in lymph node metastases compared to the primary tumors. Int. J. Mol. Sci., 18. 10.3390/ijms18081640

[39]

Sciarra "Distribution of high chromogranin A serum levels in patients with nonmetastatic and metastatic prostate adenocarcinoma" Urol. Int. (2009) 10.1159/000200789

[40]

Berruti "Chromogranin A expression in patients with hormone naïve prostate cancer predicts the development of hormone refractory disease" J. Urol. (2007) 10.1016/j.juro.2007.05.018

[41]

Giridhar "Serum chromogranin-A-based prognosis in metastatic castration-resistant prostate cancer" Prostate Cancer Prostatic Dis. (2018) 10.1038/s41391-018-0046-9

[42]

Conteduca "Chromogranin A is a potential prognostic marker in prostate cancer patients treated with enzalutamide" Prostate (2014) 10.1002/pros.22890

[43]

Burgio "Chromogranin A predicts outcome in prostate cancer patients treated with abiraterone" Endocr. Relat. Cancer (2014) 10.1530/erc-14-0071

[44]

Fan "Chromogranin A and neurone-specific enolase variations during the first 3 months of abiraterone therapy predict outcomes in patients with metastatic castration-resistant prostate cancer" BJU Int. (2017) 10.1111/bju.13781

[45]

Heck "Chromogranin A and neurone-specific enolase serum levels as predictors of treatment outcome in patients with metastatic castration-resistant prostate cancer undergoing abiraterone therapy" BJU Int. (2017) 10.1111/bju.13493

[46]

Reis "Assessment of serum chromogranin-A as prognostic factor in high-risk prostate cancer" J. Investig. Med. (2010) 10.2310/jim.0b013e3181f5d610

[47]

Fan "Neuroendocrine differentiation markers guide treatment sequence selection in metastatic castration-resistant prostate cancer" Prostate (2019) 10.1002/pros.23762

[48]

Koochekpour "Serum glutamate levels correlate with Gleason score and glutamate blockade decreases proliferation, migration, and invasion and induces apoptosis in prostate cancer cells" Clin. Cancer Res. (2012) 10.1158/1078-0432.ccr-12-1308

[49]

Schmidt, J.A., Fensom, G.K., Rinaldi, S., Scalbert, A., Appleby, P.N., Achaintre, D., Gicquiau, A., Gunter, M.J., Ferrari, P., and Kaaks, R. (2017). Pre-diagnostic metabolite concentrations and prostate cancer risk in 1077 cases and 1077 matched controls in the European Prospective Investigation into Cancer and Nutrition. BMC Med., 15. 10.1186/s12916-017-0885-6

[50]

Huang "Prospective serum metabolomic profiling of lethal prostate cancer" Int. J. Cancer (2019) 10.1002/ijc.32218

Showing 50 of 55 references

Cited By

57

Integrative analysis of urinary microRNAs for prostate cancer detection: A proof-of-concept study

Leila Asadi Samani, Saeid Rahmani · 2026

Translational Oncology

Metrics

57

Citations

55

References

Details

Published: Jul 31, 2020
Vol/Issue: 10(8)
Pages: 549
License: View

Authors

H

Helen Saxby

St Luke’s Cancer Center, Royal Surrey County Hospital, Egerton Rd, Guildford GU2 7XX, UK

C

Christos Mikropoulos

St Luke’s Cancer Center, Royal Surrey County Hospital, Egerton Rd, Guildford GU2 7XX, UK

S

Stergios Boussios

Medway NHS Foundation Trust, Windmill Road, Gillingham, Kent ME7 5NY, UK; AELIA Organization, 9th Km Thessaloniki-Thermi, 57001 Thessaloniki, Greece

Cite This Article

Helen Saxby, Christos Mikropoulos, Stergios Boussios (2020). An Update on the Prognostic and Predictive Serum Biomarkers in Metastatic Prostate Cancer. Diagnostics, 10(8), 549. https://doi.org/10.3390/diagnostics10080549

An Update on the Prognostic and Predictive Serum Biomarkers in Metastatic Prostate Cancer

You May Also Like